Recent normative systems and risk factors in polymyalgia rheumatica
Authors:
Hrnčíř Zb 1; J. Brtková 2
Authors place of work:
II. interní gastroenterologická klinika Lékařské fakulty UK a Fakultní nemocnice, Hradec Králové
1; Radiologická klinika Lékařské fakulty UK a Fakultní nemocnice, Hradec Králové
2
Published in the journal:
Čes. Revmatol., 24, 2016, No. 2, p. 38-46.
Category:
Review Article
Summary
Polymyalgia rheumatica (PMR) is a clinical syndrome characterized by pain and stiffness in the neck, shoulder and pelvic girdles; this disorder is the most frequent inflammatory rheumatism in the elderly (caucasian) population. Difficulties in differential diagnosis and therapeutic protocols in PMR, but also progress of technology (esspecially in ultrasonographic imageing) induced within the past decade initiatives for definition of more precised guidelines (BSR/BHPR 2010), original classification criteria (EULAR/ACR 2012), and recommendation for management of PMR (EULAR/ACR 2015): they are the „State-of-the-Art“ in PMR and represent the background of this paper. At the same time a large amount of knowledge was obtained in relation to the most important risk factors in PMR, i. e. in relation to overlap with giant cell arteritis, probability of malignant tumours, responsivity and/or toxicity of long term therapy, esspecially do to glucocorticoids, etc. Recent normative systems may limit risk factors in PMR, and up-to-date information on this progress in PMR is an important precondition for good clinical practice, especially in rheumatology.
Key words:
Polymyalgia rheumatica, classification criteria, scoring algorithms, glucocorticoids, giant cell arteritis, risk of neoplasms
Zdroje
1. Rooney PJ, Rooney J, Balint G, Balint P. Polymyalgia rheumatica: 25 years of epidemiological progress? Scotish Med J 2015; 60: 50–7.
2. Bruce W. Senile rheumatic gout. Brit Med J 1888; 2: 811–3.
3. Barber HS. Myalgic syndrome with constitutional effects. Polymyalgia rheumatica. Ann Rheum Dis 1957;16:230-7.
4. Bird HA, Esselinckx W, Dixon AStJ, Mawat AG, Wood PHN. An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis 1979; 38: 434–9.
5. Jones JG, Hazleman BL. Prognosis and management of polymyalgia rheumatica. Ann Rheum Dis 1981;40:1-5.
6. Chuang TY, Hunder GG, Ilstrup DM, Kurland LT. Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann Intern Med 1982; 97: 672–80.
7. Nabunaga M, Yashioka K, Yasuada M, Shingu M. Clinical studies of polymyalgia rheumatica: a proposal diagnostic criteria. Jap J Med 1989; 28: 452–6.
8. Bird HA, Leeb BF, Montecucco CM, Misiuniene N, Nesher G, Pai S, et al. A comparison of the sensitivity of diagnostic criteria for polymyalgia rheumatica. Ann Rheum Dis 2005; 64: 626–9.
9. Dasgupta B, Borg FA, Hassan N, Barraclough K, Bourke B, Fulcher J, et al. BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology 2010; 49: 186–90.
10. Dasgupta B, Cimmino MA, Kremers HM, Schmidt WA, Schirmer M, Salvarani C, et al. 2012 provisional classification criteria for polymyalgia rheumatica. Arthritis Rheum 2012; 64: 943–54.
11. Dejaco Ch, Singh YP, Perel P, Hutchings A, Camellino D, Mackie S, et al. 2015 recommendation for the management of polymyalgia rheumatica. Arthritis Rheum 2015; 67: 2569–80.
12. Aggarwal R, Ringold S, Khanna D, Neogi T, Johnson SR, Miller A, et al. Distinctions between diagnostic and classification criteria? Arthritis Care Res 2015; 67: 891–7.
13. Weigand S, Ehrenstein B, Fleck M, Hartung W. Joint involvement in patients with early polymyalgia rheumatica using high-resolution ultrasound and its contribution to the EULAR/ACR 2012 classification criteria for polymylagia rheumatica. J Rheumatol 2014;41: 730–34.
14. Macchioni P, Boiardi L, Catanoso M, Pazzola G, Salvarani C. Performance of the new 2012 EULAR/ACR classification criteria for polymyalgia rheumatica: comparison with the previous criteria in a single-centre study. Ann Rheum Dis 2014; 73: 1190–3.
15. Lopez-Hoyos M, Ruiz de Alegria C, Blanco R, Crespo J, Peňa M, Rodrigez-Valverde V, et al. Clinical utility of anti-CCP antibodies in the differential diagnosis of elderly-onset rheumatoid arthritis and polymyalgia rheumatica. Rheumatology 2004; 43: 655–7.
16. Caylor TL, Perkins A. Recognition and management of polymyalgia rheumatica and giant cell arteritis. Am Fam Physician 2013; 88: 676–684.
17. Smetana GW, Shmerling RH. Does this patient have temporal arteritis? JAMA 2002; 287: 92–101.
18. Warrington KJ, Weyand CM. Giant cell arteritis and polymyalgia rheumatica. In: Ball GV, Fessler FJ, Bridges SL Jr (eds) Oxford Textbook of Vasculitis. 3rd ed. Oxford: Oxford University Press; 2014, p. 307–18.
19. Gonzales-Gay MA, Carcia-Porrua C, Amor-Dorado JC. Llorca J. Fever in biopsy-proven giant cell arteritis: clinical implication in a defined population. Arthritis Care Res 2004; 51: 652–5.
20. Rencová E, Hrnčíř Zb, Rozsíval P. Oční projevy u revmatických chorob. In: Rozsíval P (editor) Trendy soudobé oftalmologie. 1st ed. Praha: Galén; 2006, p. 135–82.
21. Muller S, Hider SL, Belcher J, Helliwell T, Mallen ChD. Is cancer associated with polymyalgia rheumatica? A cohort study in the General Practice Research Database. Ann Rheum Dis 2014; 73: 1769–73.
22. Jinguang J, Xiangdong L, Sundquist K, Sundquist J, Hemminki K. Cancer risk in patients hospitalized with polymyalgia rheumatica and giant cell arteritis: a follow-up study in Sweden. Rheumatology 2010; 49: 1158–63.
23. Witlock M, Hollywood J. Treatment guidelines for polymyalgia rheumatica: the nursing perspective. Rheumatology 2014; 53 (Suppl 2): 10.
24. Ramiro S, Gaujoux-Viala C, Nam JL, Smolen JS, Buch M, Gossec L, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2014; 73: 529–35.
25. Hellmann DB. Giant cell arteritis, polymyalgia rheumatica, and Takayasu´s arteritis. In: Firestein GS, Budd RC, Gabriel SE, McInnes IB, O´Dell JR. (eds) Kelley´s Textbook of Rheumatology. 9th ed. Philadelphia: Elsevier; 2013, p. 1461–80.
26. Aikawa NE, Pereira RMR, Lage L, Bonfá E, Carvalho JF. Anti-THF therapy for polymyalgia rheumatica: report of 99 cases and review of the literature. Clin Rheumatol 2012; 31: 575–79.
27. Rashidi A, Hegazi MO, Mohammad SA, Varghese A. Effective control of polymyalgia rheumatica with tocilizumab. J Clin Rheumatol 2013; 19: 400–1.
28. Unizony S, Arias-Urdaneta L, Miroslavsky E, Arvikar E, Khosroshahi A, Keroak B, et al. Tocilizumab for the treatment of large-vessel vasculitis (Giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res 2012; 64: 1720–9.
29. Leeb BF, Bird HA. A disease aktivity score for polymyalgia rheumatica. Ann Rheum Dis 2004; 63: 1279–83.
30. Dejaco Ch, Duftner Ch, Cimmino MA, Dasgupta B, Salvarani C, Crowson CS, et al. Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus. Ann Rheum Dis 2011; 70: 447–53.
31. Salvaranti C, Cantini F, Niccoli L, Machioni P, Consonni D, Bajocchi G, et al. Acute-phase reactants and the risk of relapse/recurence in polymyalgia rheumatica: a prospective follow up study. Arthritis Care Res 2005; 53: 33–8.
32. van der Goes MC, Jacobs JWG, Jurgens MS, Bakker MF, van der Veen, van der Werf et al. Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to a tight control strategy with or without prednisone of osteoporosis prophylaxis in applied? Osteoporos Int 2013; 24: 1429–36.
33. Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W et al.: „American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis“. Arthritis Care Res 2010; 62: 1515–26.
Štítky
Dermatology & STDs Paediatric rheumatology RheumatologyČlánok vyšiel v časopise
Czech Rheumatology
2016 Číslo 2
Najčítanejšie v tomto čísle
- Severe case of Crohn’s disease with extraintestinal joint manifestation and psoriasis
- Recent normative systems and risk factors in polymyalgia rheumatica